Latest Dilution News

Page 18 of 282
Elementos has materially strengthened its balance sheet while moving its Spanish Oropesa tin project closer to permitting, financing and a final investment decision. The annual report also highlights a doubling of Cleveland’s inferred tungsten resource, but both projects still require substantial capital and further approvals.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Flynn Gold has returned to trading with a one-for-three renounceable rights issue priced at A$0.015, seeking up to approximately A$3 million for Tasmanian exploration. Only A$1.5 million is underwritten, leaving the final proceeds dependent on shareholder participation and shortfall demand.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Silver Mines is seeking A$70 million from investors while agreeing to spend A$26 million to remove two private royalties from its Bowdens Silver Project. The strategy could simplify Bowdens’ economics, but the royalty deals depend on securing at least A$50 million in placement commitments and meeting approval conditions.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.
Ada Torres
Ada Torres
21 Sept 2026
Wildcat Resources has secured firm commitments for a A$60 million institutional placement to push Tabba Tabba into engineering, site establishment and construction readiness ahead of a definitive feasibility study targeted for later in 2026. The raise strengthens funding, but part of the share issue still requires shareholder approval and the financing does not establish a final investment decision.
Maxwell Dee
Maxwell Dee
21 Sept 2026
IVE Group has agreed to acquire digital place-based media operator Motio for approximately $20.7 million, adding more than 1,300 screens to its marketing platform. The transaction is expected to be earnings and EPS accretive, but remains subject to shareholder, Court and other conditions.
Victor Sage
Victor Sage
21 Sept 2026
Enterprise Metals has secured $1.2 million in discounted equity funding alongside a proposed board overhaul led by mining executives Phillip Gallagher and Steven Zaninovich. The incoming team will review the company’s Western Australian portfolio and decide where its limited exploration capital should go next.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Forrestania Resources has agreed to acquire four granted Western Australian exploration licences at Skeleton Rocks for a stated $250,000 consideration. The deal remains subject to due diligence, with the company yet to choose between cash and shares as payment.
Maxwell Dee
Maxwell Dee
21 Sept 2026
BOA Resources has returned high-grade copper intersections from all six initial RC holes at Ricci Lee, including 14 metres at 2.49% copper and 15 metres at 2.25%. Assays from 40 further RC holes and 92 aircore holes across five other prospects remain pending.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Nexus Minerals has secured firm commitments for a A$5.4 million placement to fund drilling and exploration across its Wallbrook Gold Project and NSW Mineral Project. The raise is priced below recent market benchmarks and is expected to lift cash above A$8.7 million before costs.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Metal Hawk has secured $1.2 million from sophisticated investors as RC drilling begins at the Numbat lode in Western Australia. The campaign will test whether the company’s strongest Leinster South gold intercept extends along strike and at depth.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
Ada Torres
Ada Torres
21 Sept 2026

Browse the archive

Full archive